The administration of antibodies blocking the immune checkpoint molecules programmed
cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) has evolved as a very promising
treatment option for cancer patients. PD-1/PD-L1 inhibition has significantly enhanced expansion,
cytokine secretion, and cytotoxic activity of CD4+ and CD8+ T lymphocytes, resulting in enhanced
antitumor responses. Anti-PD-1 or anti-PD-L1 therapy has induced tumor regression and improved
clinical outcome in patients with different tumor entities, including melanoma, non-small-cell lung
cancer, and renal cell carcinoma. These findings led to the approval of various anti-PD-1 or anti-PD-L1
antibodies for the treatment of tumor patients. However, the majority of patients have failed to
respond to this treatment modality. Comprehensive immune monitoring of clinical trials led to
the identification of potential biomarkers distinguishing between responders and non-responders,
the discovery of modes of treatment resistance, and the design of improved immunotherapeutic
strategies. In this review article, we summarize the evolving landscape of biomarkers for anti-PD-1
or anti-PD-L1 therapy.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:84639 |
| Date | 06 April 2023 |
| Creators | Tunger, Antje, Sommer, Ulrich, Wehner, Rebekka, Kubasch, Anne Sophie, Grimm, Marc-Oliver, Bachmann, Michael Philipp, Platzbecker, Uwe, Bornhäuser, Martin, Baretton, Gustavo, Schmitz, Marc |
| Publisher | MDPI |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 2077-0383, 1534 |
Page generated in 0.002 seconds